PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
US9663789B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2014 |
| Grant date | May 30, 2017 |
| Priority date | — |
| Expiry date | Oct 15, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/918
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.